ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: FR-PO1190

Surveillance Biopsy-Driven Steroid Withdrawal

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical

Authors

  • Weekers, Laurent E., CHU ULg, Esneux, Belgium
  • Pottel, Hans, KULeuven, Kortrijk, Belgium
  • Bonvoisin, Catherine, CHU ULg, Esneux, Belgium
  • Jouret, Francois, University of Liege Hospital (ULg CHU), Liege, Belgium
Background

Steroids withdrawal (SW) is the most frequently used IS minimizing-strategy, but it increases the risk of AR. We reasoned that surveillance biopsy (SB) could help individualized selection of patients with low risk of AR after SW. We implemented a systematic SB-driven SW protocol since 2007. We present a critical appraisal of the safety, efficiency and utility of this procedure.

Methods

Mono-centric analysis of all KTx performed from 2007 to 2015 and followed until March 2019. SB was performed at a prednisolone dose of 5 mg. SW was only allowed in kidney transplant (KT) with no sign of rejection (including borderline). Combining the two possible interventions (SB and SW) and adherence to the clinical protocol, we defined 6 groups as depicted in the study flow-chart.
The safety and efficiency analysis are purely descriptive. The primary end-point for the utility analysis is the prevalence of late (occurring after the intervention) AR and the secondary is time-to-event analysis (Cox model) of a combination of graft lost or eGFR decline>30% from 1 to 3 years post-KTx.

Results

The complication rate after SB was 2,5%: 1,8 % requiring non- or minimally-invasive intervention and 0,3% necessitating an embolization. No graft lost or procedure-related death was encountered.
Out of the 481 KTx analyzed, 169 (35%) were withdrawn from steroids after SB and 97 (20%) showed some degree of SCAR.
Rate of late AR were distributed as follow: [SW pp] 6%, [No SW vp] 8%, [No SW pp] 14% and [SW vp] 22% (Chi-2 for trend 0.008).
Breakdown of the population according to pre-specified groups was associated to the secondary end-point in both total (p=0.0002) and death-censored (p=0.019) in univariate analysis with [SW pp] being among the best survival groups.

Conclusion

SB-driven SW was safe and associated with good long term outcome.